Literature DB >> 3570163

Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens.

G M Hill, G J Brewer, A S Prasad, C R Hydrick, D E Hartmann.   

Abstract

The standard therapy for preventing copper accumulation in Wilson's disease, D-penicillamine, has been a life-saving drug, but it has many side effects and some patients are completely intolerant. We have been using oral zinc as another approach to the therapy for Wilson's disease, with copper balance studies as the key initial assessment of the adequacy of a given dose or regimen of zinc therapy. We earlier reported that an intensive regimen of zinc (zinc taken every 4 hr) was effective in controlling copper balance. We have now shown with balance studies that a simplified zinc therapy regimen of 50 mg zinc taken 3 times per day is effective in controlling copper balance. Preliminary work presented here with other simplified regimens also indicate their effectiveness. These studies increase the data base, in terms of copper balance, for zinc therapy of Wilson's disease, and expand the dose range and regimens of zinc which have been shown to control copper balance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3570163     DOI: 10.1002/hep.1840070318

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

Review 1.  Current therapy of chronic liver disease.

Authors:  M W Stavinoha; R D Soloway
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

2.  Hepatocellular copper toxicity and its attenuation by zinc.

Authors:  M L Schilsky; R R Blank; M J Czaja; M A Zern; I H Scheinberg; R J Stockert; I Sternlieb
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

Review 3.  A review and current perspective on Wilson disease.

Authors:  Mallikarjun Patil; Keyur A Sheth; Adarsh C Krishnamurthy; Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2013-07-06

Review 4.  Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring.

Authors:  Karl Heinz Weiss; Wolfgang Stremmel
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 5.  Practical recommendations and new therapies for Wilson's disease.

Authors:  G J Brewer
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

6.  Absorption and metabolism of oral zinc gluconate in humans in fasting state, during, and after a meal.

Authors:  J Nève; M Hanocq; A Peretz; F A Khalil; F Pelen
Journal:  Biol Trace Elem Res       Date:  1992 Jan-Mar       Impact factor: 3.738

7.  Linkage of the Wilson disease gene to chromosome 13 in North-American pedigrees.

Authors:  V Yuzbasiyan-Gurkan; G J Brewer; E Boerwinkle; P J Venta
Journal:  Am J Hum Genet       Date:  1988-06       Impact factor: 11.025

8.  Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration.

Authors:  C Hartard; B Weisner; C Dieu; K Kunze
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

9.  Serum trace metals in chronic viral hepatitis and hepatocellular carcinoma in Thailand.

Authors:  C Pramoolsinsap; N Promvanit; S Komindr; P Lerdverasirikul; S Srianujata
Journal:  J Gastroenterol       Date:  1994-10       Impact factor: 7.527

10.  Issues raised involving the copper hypotheses in the causation of Alzheimer's disease.

Authors:  George J Brewer
Journal:  Int J Alzheimers Dis       Date:  2011-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.